Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH Dec 12, 2022
Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 Negative Dec 8, 2022
Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial Nov 3, 2022
Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization Nov 2, 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Oct 31, 2022
Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A Oct 27, 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B Oct 25, 2022
Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones Sep 21, 2022
